Hepatitis C in the UK 2023: accessible text for infographic
Updated 7 March 2024
© Crown copyright 2024
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/hepatitis-c-in-the-uk/hepatitis-c-in-the-uk-2023-accessible-text-for-infographic
Three out of 4 people people with hepatitis C (HCV) are recorded as engaged in care. Once engaged, 90% initiate treatment.
93,000 people in the UK were living with chronic HCV in 2021 (modelled estimates). This is a 49% reduction from 2015.
Provision of needles and syringes (NSP) remains a challenge and has been impacted by the coronavirus (COVID-19) pandemic.
HCV mortality and morbidity in the UK have reduced since 2015 likely a result of increased access to direct-acting antivirals (DAAs).
At the current rate of decline in prevalence, the UK should meet the World Health Organization (WHO) elimination target by 2030. However, less than half of people who inject drugs who have ever had HCV are aware of their diagnosis.
This impacts new infections and reinfections. Around 4% of people who have been treated for HCV have a re-infection.